CoChat

Randomized, Double‐Blind, Placebo‐Controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis

Open access
Ilowite, Norman T., Prather, Kristi, Lokhnygina, Yuliya, Schanberg, Laura E., Elder, Melissa, Milojevic, Diana, Verbsky, James W., Spalding, Steven J., Kimura, Yukiko, Imundo, Lisa F., Punaro, Marilynn G., Sherry, David D., Tarvin, Stacey E., Zemel, Lawrence S., Birmingham, James D., Gottlieb, Beth S., Miller, Michael L., O'Neil, Kathleen, Ruth, Natasha M., Wallace, Carol A., Singer, Nora G., Sandborg, Christy I. · 2014 · Arthritis & Rheumatology
Cited by 167

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Objective: To assess the efficacy and safety of rilonacept, an interleukin‐1 inhibitor, in a randomized, double‐blind, placebo‐controlled trial. Methods: An initial 4‐week double‐blind placebo phase was incorporated into a 24‐week randomized multicenter design, followed by an open‐label phase. Seventy‐one children who had active arthritis in ≥2 joints were randomized (1:1) to the 2 arms of the study. Patients in the rilonacept arm received rilonacept (loading dose 4.4 mg/kg followed by 2.2 mg/kg weekly, subcutaneously) beginning on day 0. Patients in the placebo arm received placebo for 4 weeks followed by a loading dose of rilonacept at week 4 followed by weekly maintenance doses. The primary end point was time to response, using the adapted American College of Rheumatology Pediatric 30 criteria coupled with the absence of fever and taper of the dosage of systemic corticosteroids, using prespecified criteria. Results: The time to response was shorter in the rilonacept arm than in the placebo arm (χ 2 = 7.235, P = 0.007). The secondary analysis, which used the same response criteria, showed that 20 (57%) of 35 patients in the rilonacept arm had a response at week 4 compared with 9 (27%) of 33 patients in the placebo arm (P = 0.016). Exacerbation of systemic juvenile idiopathic arthritis (JIA) was the most common severe adverse event. More patients in the rilonacept arm had elevated liver transaminase levels (including levels more than 3 times the upper limit of normal) compared with those in the placebo arm. Adverse events were similar in the 2 arms of the study. Conclusion: Rilonacept was generally well tolerated and demonstrated efficacy in active systemic JIA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.38699

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 167

Metadata

Authors
Ilowite, N. T., Prather, K., Lokhnygina, Y., Schanberg, L. E., Elder, M., Milojevic, D., Verbsky, J. W., Spalding, S. J., Kimura, Y., Imundo, L. F., Punaro, M. G., Sherry, D. D., Tarvin, S. E., Zemel, L. S., Birmingham, J. D., Gottlieb, B. S., Miller, M. L., O'Neil, K., Ruth, N. M., Wallace, C. A., Singer, N. G., & Sandborg, C. I.
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2014-08-26
Volume
66
Issue
9
Pages
2570-2579
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W1779387069
Cited by
167
References
2
FWCI
11.22
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized, Double‐Blind, Placebo‐Controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis. https://app.cochat.ai/papers/10.1002/art.38699
The paper
Ilowite, N. T., Prather, K., Lokhnygina, Y., Schanberg, L. E., Elder, M., Milojevic, D., Verbsky, J. W., Spalding, S. J., Kimura, Y., Imundo, L. F., Punaro, M. G., Sherry, D. D., Tarvin, S. E., Zemel, L. S., Birmingham, J. D., Gottlieb, B. S., Miller, M. L., O'Neil, K., Ruth, N. M., . . . Sandborg, C. I. (2014). Randomized, Double‐Blind, Placebo‐Controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis. Arthritis & Rheumatology. https://doi.org/10.1002/art.38699

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.